Kevin B. Sippy
AbbVie (United States)(US)
Publications by Year
Research Areas
Synthesis and Biological Evaluation, Urinary Bladder and Prostate Research, Hormonal and reproductive studies, Receptor Mechanisms and Signaling, Nicotinic Acetylcholine Receptors Study
Most-Cited Works
- → Synthesis and Structure−Activity Relationship Studies of 3,6-Diazabicyclo[3.2.0]heptanes as Novel α4β2 Nicotinic Acetylcholine Receptor Selective Agonists(2007)46 cited
- → Structure−Activity Studies for a Novel Series of Tricyclic Substituted Hexahydrobenz[e]isoindole α1A Adrenoceptor Antagonists as Potential Agents for the Symptomatic Treatment of Benign Prostatic Hyperplasia (BPH)(2000)43 cited
- → SAR of α7 nicotinic receptor agonists derived from tilorone: Exploration of a novel nicotinic pharmacophore(2012)34 cited
- → Structure−Activity Studies for a Novel Series ofN-(Arylethyl)-N-(1,2,3,4-tetrahydronaphthalen-1-ylmethyl)-N-methylamines Possessing Dual 5-HT Uptake Inhibiting and α2-Antagonistic Activities(1997)34 cited
- → Structure−Activity Studies for a Novel Series of Bicyclic Substituted Hexahydrobenz[e]isoindole α1A Adrenoceptor Antagonists as Potential Agents for the Symptomatic Treatment of Benign Prostatic Hyperplasia(2001)33 cited
- → Preparation and characterization of N-(3-pyridinyl) spirocyclic diamines as ligands for nicotinic acetylcholine receptors(2009)30 cited
- → Two Novel and Potent 3-[(o-Methoxyphenyl)piperazinylethyl]-5-phenylthieno[2,3-d]pyrimidine-2,4-diones Selective for the α1D Receptor(2001)25 cited
- → Synthesis and Pharmacological Characterization of 3-[2-((3aR,9bR)-cis-6-Methoxy- 2,3,3a,4,5,9b-hexahydro-1H- benz[e]isoindol-2-yl)ethyl]pyrido[3‘,4‘:4,5]thieno[3,2-d]pyrimidine- 2,4(1H,3H)-dione (A-131701): A Uroselective α1A Adrenoceptor Antagonist for the Symptomatic Treatment of Benign Prostatic Hyperplasia(1997)19 cited
- → Discovery of fused azetidines as novel selective α4β2 neuronal nicotinic receptor (NNR) agonists(2005)13 cited
- → Synthesis and pharmacological characterization of A-80426: A putative novel antidepressant combining α-2 antagonism with 5-HT uptake inhibition(1995)7 cited